deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT00492050

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection

Sponsor: M.D. Anderson Cancer Center

Conditions Waldenstrom's Macroglobulinemia
Interventions Bortezomib Rituximab Valacyclovir
Updated 19 times since 2017 Last updated: Feb 17, 2026 Started: Aug 2, 2006 Primary completion: Feb 28, 2021 Completion: Jun 28, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00492050, this PHASE2 trial focuses on Waldenstrom's Macroglobulinemia and remains ongoing. Sponsored by M.D. Anderson Cancer Center, it has been updated 19 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~May 2020 · 11 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~Oct 2023 · 9 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Apr 2025 · 5 months · monthly snapshot~Apr 2025 – ~Oct 2025 · 6 months · monthly snapshot~Oct 2025 – ~Mar 2026 · 5 months · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  7. May 2022 — Jun 2022 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  8. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  9. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  12. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Feb 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • Millennium Pharmaceuticals, Inc.
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations